ARA-290 (Cibinetide) Peptide – Premium Innate Repair Receptor Agonist for Research

ARA-290 (Cibinetide) – Non-Hematopoietic EPO-Derived Research Peptide

ARA-290, also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the helix B surface domain of erythropoietin (EPO) . Unlike full-length EPO, ARA-290 is non-erythropoietic—it does not stimulate red blood cell production—but retains potent tissue-protective and anti-inflammatory properties through selective activation of the Innate Repair Receptor (IRR) . This targeted mechanism makes ARA-290 a compelling research tool for investigating neuropathy, metabolic disorders, and inflammation-driven tissue damage. This research-grade peptide is strictly for laboratory investigation and is not intended for human consumption.

Key Factual Details

Mechanism of Action & Research Applications

Selective Innate Repair Receptor (IRR) Activation: ARA-290 binds to the heterodimeric IRR composed of the erythropoietin receptor (EPOR) and the β-common receptor (CD131), which is upregulated in tissues under stress, inflammation, or metabolic insult . This initiates a cascade of pro-survival and anti-inflammatory signaling through the JAK2/STAT, PI3K/Akt pathways, and inhibits the NF-κB inflammatory pathway .

Research Applications:

• Neuropathy & Nerve Regeneration: Preclinical and clinical data demonstrate improvements in corneal nerve fiber density (CNFD) and reductions in neuropathic pain scores 

• Cardiovascular Aging: Reduces cardiac inflammation, preserves left ventricular ejection fraction, and ameliorates frailty in aged models 

• Diabetic Research: Improves glucose tolerance and insulin release in type 2 diabetic models 

• Inflammatory Disorders: Suppresses pro-inflammatory cytokines via NF-κB inhibition 

• Anti-Apoptotic Studies: Enhances cell survival and reduces apoptosis in stressed tissues 

Research Parameters

All dosages are for in-vitro and preclinical research use only and are not intended for human consumption.

Preclinical Rodent Dosing :

• Typical Dose: 30-70 µg/kg body weight

• Route: Subcutaneous (SC) or intraperitoneal (IP) injection

• Frequency: Once daily

• Study Duration: 4-28 days or chronic (15-month) protocols

Clinical Research Dosing (Published Data) :

• Standard Dose: 2-4 mg daily

• Route: Subcutaneous (SC) injection

• Protocol: 28-day continuous daily dosing

• Cycle: 4 weeks on, followed by 8-12 weeks off before another cycle 

Storage:

• Store lyophilized powder at -20°C

• Protect from light and moisture